Quantcast

Latest Docetaxel Stories

2014-04-03 08:28:53

TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI(®) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet...

2014-03-24 16:24:53

TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI(®) capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013. XTANDI is a once-daily, oral androgen receptor signaling inhibitor that acts on...

2014-02-19 08:31:13

-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC), showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm...

2014-02-11 08:30:37

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer...

2014-02-05 12:28:11

The Majority of Current Non-Prescribers Anticipate Prescribing Xofigo within the Next Year, According to Findings from Decision Resources Group BURLINGTON, Mass., Feb. 5, 2014 /PRNewswire/ -- Decision Resources Group finds that at six month post-launch in the United States, approximately two-thirds of surveyed U.S. medical oncologists have prescribed Algeta/Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to...

2013-12-09 23:21:19

Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA (PRWEB) December 09, 2013 Men suffering from highly advanced prostate cancer have new hope for longer survival times based on a recent clinical trial, the interim results of which were just announced by the National Institutes of Health. The findings suggest that physicians can immediately consider changing their clinical practice...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.